重庆博腾药业有限公司

As a world leading pharmaceutical CDMO, Porton provides global partners with efficient, flexible and high-quality one-stop solutions from small molecular APIs development to commercial supply. To broaden our service to downstream and enhance end-to-end delivery capability, Porton Pharmaceutical Division is established this July, with R&D centers in Shanghai and Chongqing, GMP pilot plant and commercial manufacturing sites in Chongqing. We are committed to build a drug formulation development and manufacturing service platform with state of art facilities and experienced core team, together with Porton’s API supply strength, deliver an integrated service for our partners.

The business scope of Porton Pharmaceutical Division includes pre-formulation study, formulation process development, clinical supply and commercial drug product manufacturing, covering dosage forms from various oral solids to injections and high-end complex formulations. The first phase of R&D center will be put into use in the first quarter of 2020, and the multi-purpose formulation workshops designed based on FDA and EU standards are planned to be completed in 2021.

At present, we are recruiting talents from both China and overseas. We have an energetic team with spirit of innovation in Porton family and expect you to join us!

重庆博腾药业有限公司于2019年成立， 是上市公司博腾股份（股票代码：300363）控股子公司，公司致力于打造全球领先的制剂研发生产服务平台，已在上海和重庆设立研发中心, 在重庆设立GMP中试及商业化生产基地。

母公司博腾股份成立于2005年7月，是国内领先的医药研发生产外包组织（CDMO）。十多年来，博腾股份坚持服务于创新药领域，积累了领先的研发技术平台能力、完善的质量管理和EHS管理体系，持续为强生、吉利德、辉瑞、葛兰素史克、诺华、罗氏、勃林格殷格翰等全球知名制药公司及药物研发机构提供服务。公司在中国（重庆、成都、上海、江西、香港）、美国、比利时、瑞士、英国设有运营及分支机构，拥有全球雇员1800余人。

博腾药业的成立，将充分发挥博腾上下游协同效应，与已有的国际领先的小分子药物工艺研发和生产平台形成合力，为全球制药企业和药物研发机构提供药物开发CMC服务、MAH委托生产服务、原料药到制剂的端到端定制研发及生产服务。

博腾药业是一个积极创新、充满活力的团队，我们热切期待海内外有志之士加盟，共同为提升中国制药能力添砖加瓦，让新药更快惠及更多患者。

公司官网：http://www.porton.cn/